3 recruiting, 2 completed, 1 temporarily not available. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Fibrodysplasia Ossificans Progressiva (FOP): new trials by email Literature Review of Fibrodysplasia Ossificans Progressiva (FOP) trials Research Report on Fibrodysplasia Ossificans Progressiva (FOP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IL1 Inhibition in FOP Anti-IL1 Therapy - Fibrodysplasia Ossificans Progressiva (FOP) | Recruiting | University of California, San Francisco | 11 | 2025-04-01 | 2026-08-06 | |
| A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP) Non-Interventional - Fibrodysplasia Ossificans Progressiva (FOP) | Completed | Regeneron Pharmaceuticals | 131 | 2023-06-29 | 2025-07-03 | |
| To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva INCB000928, Placebo - Fibrodysplasia Ossificans Progressiva (FOP) | Phase 2 | Recruiting | Incyte Corporation | 98 | 2022-05-05 | 2026-10-22 |
| A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. Palovarotene - Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 | Completed | Ipsen | 61 | 2022-03-14 | 2025-06-22 |
| The Fibrodysplasia Ossificans Progressiva (FOP) Registry Fibrodysplasia Ossificans Progressiva (FOP) | Recruiting | The International FOP Association | 800 | 2015-07-01 | 2026-04-08 | |
| An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) Garetosmab - Fibrodysplasia Ossificans Progressiva (FOP) | Temporarily not available | Regeneron Pharmaceuticals | 2025-12-24 |
Myositis Ossificans (6) · Ossification, Heterotopic (4) · Genetic Diseases, Inborn (1) · Hallux Valgus (1) · Mucopolysaccharidosis IV (1) · Osteochondroma (1)
Muscular Diseases (6) · Musculoskeletal Diseases (6) · Myositis (6) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Foot Deformities (1) · Lysosomal Storage Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Mucinoses (1)
Interleukin 1 Receptor Antagonist Protein (1) · Palovarotene (1) · canakinumab (1)
Regeneron Pharmaceuticals (2) · Incyte Corporation (1) · Ipsen (1) · The International FOP Association (1) · University of California, San Francisco (1)
United States (5) · Argentina (2) · Australia (2) · Brazil (2) · Canada (2) · France (2) · Italy (2) · Spain (2) · United Kingdom (2) · Chile (1) · China (1) · Germany (1) · Mexico (1) · Netherlands (1) · New Zealand (1)
Amanda McBride, MD (1) · Edward Hsiao, MD, PhD (1) · Mark Hamilton, PhD (1)
2023 (1), R01AR083628 (1)